Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion

Exicure is selling its GPC-100 program for KRW 6.5 billion to GPCRT Inc.

What the company is saying

Exicure, Inc. is announcing a definitive agreement to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million). The company highlights that the assets include rights under a License and Collaboration Agreement dated January 19, 2025, as well as associated contracts, intellectual property, clinical and regulatory data, materials, and equipment. Exicure frames the transaction as part of its ongoing evaluation of strategic alternatives aimed at maximizing stockholder value and strengthening its financial position. The announcement emphasizes the payment structure: KRW 500 million already paid, KRW 2.0 billion due on or before November 16, 2026, and KRW 4.0 billion payable at closing. The company is transparent about the transaction being subject to customary closing conditions, including required approvals, third-party consents, and possibly stockholder approval. The tone is factual and measured, with explicit mention that there is no assurance the transaction will close on the anticipated timetable or at all.

What the data suggests

The agreement commits GPCRT Inc. to pay a total of KRW 6.5 billion (about US$4.8 million) for Exicure's GPC-100 program assets, with KRW 500 million already received, KRW 2.0 billion due within a week, and KRW 4.0 billion at closing. The assets include all rights, contracts, and materials related to GPC-100, which completed Phase 2 trials in January 2026 for stem cell mobilization in multiple myeloma. After closing, GPCRT will assume future milestone and royalty obligations and all program costs incurred from September 1, 2026, while Exicure retains liabilities incurred before that date. The transaction is not yet closed and depends on regulatory, third-party, and possible stockholder approvals, as well as a waiver and release from GPCR Therapeutics, Inc. The company does not disclose its current cash position, pro forma financials, or the expected net impact of the sale, so the materiality relative to Exicure's overall financial health cannot be determined from this release alone. The payment schedule is specific and near-term, but the absence of broader financial context limits the ability to assess the full impact.

Analysis

The announcement is factual and measured, describing a signed asset sale agreement with clear payment terms and closing conditions. Most claims are realised (agreement signed, partial payment received, Phase 2 trial completed), while forward-looking statements are limited to customary closing caveats and the expectation that the sale will strengthen Exicure's financial position. The language is not promotional; it explicitly notes that closing is subject to approvals and that there is no assurance of completion. The only forward-looking claims are standard for such transactions and are not exaggerated. There is no evidence of narrative inflation or overstatement relative to the disclosed facts. The absence of profitability or pro forma financial impact disclosure limits the signal to weak_positive, but this is appropriate for an asset sale announcement at this stage.

Risk flags

• ●The transaction is subject to multiple closing conditions, including regulatory approvals, third-party consents, a waiver and release from GPCR Therapeutics, Inc., and potentially stockholder approval. Failure to secure any of these could prevent the deal from closing and delay or eliminate expected proceeds.
• ●There is no assurance that GPCRT will make the remaining payments as scheduled or that the transaction will close. If the buyer fails to pay or the deal collapses, Exicure may not realize the anticipated cash inflow.
• ●The company does not provide pro forma financials or disclose its current cash position, making it impossible to assess whether the KRW 6.5 billion sale meaningfully improves its financial stability or only provides temporary relief.
• ●Exicure and GPCR USA retain all liabilities related to the GPC-100 program incurred before September 1, 2026. If these legacy liabilities are significant, the net benefit of the transaction could be reduced or offset by ongoing obligations.
• ●The sale removes Exicure's exposure to future costs and obligations for the GPC-100 program, but also eliminates any upside from potential future milestones, royalties, or commercialization of the asset.

Bottom line

Exicure, Inc. has signed a binding agreement to sell its GPC-100 program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million), with a clear payment schedule and KRW 500 million already received. The deal is structured to transfer future costs and obligations to GPCRT, while Exicure retains pre-September 2026 liabilities. The transaction is not yet closed and faces several regulatory and procedural hurdles, including approvals and consents that could delay or derail completion. The company positions the sale as a move to strengthen its financial position, but does not provide enough financial detail to judge the true impact. Investors should focus on the completion of closing conditions and the actual receipt of funds as the next critical milestones. The most important takeaway is that while the asset sale could provide a near-term cash infusion, its ultimate benefit to Exicure depends entirely on successful closing and the scale of retained liabilities.

Announcement summary

(NASDAQ:XCUR) Exicure, Inc. announced that on November 4, 2026, it and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (GPCR USA), entered into an Intellectual Property, Asset and License Assignment Agreement with GPCRT Inc., a company organized under the laws of the Republic of Korea. Under the Agreement, GPCRT Inc. has agreed to acquire Exicure's GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US$4.8 million). The assets to be sold include Exicure's rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc. dated January 19, 2025, as well as related contracts, intellectual property, clinical and regulatory data, materials, and equipment used in the GPC-100 program. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 clinical trial of GPC-100 in January 2026. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing of the transaction. Of the KRW 6.5 billion purchase price, KRW 500 million has already been paid by GPCRT and will be credited against the purchase price, KRW 2.0 billion is payable on or before November 16, 2026, and the remaining KRW 4.0 billion is payable at closing, subject to any other payment date agreed by the parties in writing. After closing, GPCRT will assume obligations under the License and Collaboration Agreement, including future milestone and royalty payments, and under the assigned program contracts. GPCRT will also bear the costs of the GPC-100 program incurred on or after September 1, 2026, as provided in the Agreement. Exicure and GPCR USA will retain all other liabilities, including GPC-100 program liabilities incurred before September 1, 2026. The closing of the transaction is subject to customary closing conditions, including required approvals and third-party consents, a waiver and release from GPCR Therapeutics, Inc., and any approval of Exicure's stockholders that may be required. There can be no assurance that the transaction will be completed on the anticipated timetable or at all. The sale of the GPC-100 program assets is part of Exicure's ongoing evaluation of strategic alternatives intended to maximize stockholder value and is expected to strengthen the company's financial position. Additional information regarding the Agreement is included in the Current Report on Form 8-K filed by Exicure with the U.S. Securities and Exchange Commission.

Disagree with this article?